Trade-mark based medicament classification governs patent or proprietary status, with Modvat credit consequences remitted for fresh determination.

Medicaments are classifiable as patent or proprietary medicines only if the marking on the product or its packing indicates a trade connection with the manufacturer; where the mark is merely descriptive or insignificant, the goods remain generic medicaments. On the facts, unmarked capsules and tablets marked only "G" were not shown to bear such trade indication, while the remaining products required fresh examination because the earlier classification analysis was inadequate. Consequential reversal of Modvat credit could not be sustained until correct classification was determined, so the credit matters were remitted for fresh orders after reclassification.

---

---

Issues: (i) whether the medicaments bearing the marks INDOSAM, P-500, G, AMPI CLOXA, and unmarked capsules were classifiable as patent or proprietary medicines under sub-heading 3003.10 or as generic medicaments under sub-heading 3003.20; (ii) whether the orders on reversal of Modvat credit, being consequential to classification, could stand without a proper determination on classification.

Issue (i): whether the medicaments bearing the marks INDOSAM, P-500, G, AMPI CLOXA, and unmarked capsules were classifiable as patent or proprietary medicines under sub-heading 3003.10 or as generic medicaments under sub-heading 3003.20.

Analysis: The applicable test was whether the marking on the medicine or its packing indicated a connection in the course of trade between the goods and the manufacturer, thereby making the goods patent or proprietary medicines. Marks that merely described the product, or were too insignificant to indicate such a connection, would not take the goods out of the generic category. The unmarked capsules and the tablets bearing only the mark G were not shown to carry any trade indication linking them to the manufacturer. As to the remaining products, the earlier authorities had not properly analysed the markings on the tablets, capsules, and containers before characterising them as house marks, and that approach was inadequate for a valid classification.

Conclusion: Compound Magnesium Trisilicate, Amoxyciline capsules, and Cloxociline Capsules were held classifiable under sub-heading 3003.20. The classification of the remaining products was set aside for fresh determination by the jurisdictional Assistant or Deputy Commissioner.

Issue (ii): whether the orders on reversal of Modvat credit, being consequential to classification, could stand without a proper determination on classification.

Analysis: Since the duty consequences depended upon the correct classification of the medicaments, the reversal of Modvat credit could not be finally sustained without first deciding the classification issue for the disputed products. The existing orders were therefore not capable of being affirmed in full.

Conclusion: The Modvat credit matters were remanded for fresh orders after the classification issue was decided.

Final Conclusion: The decision affirmed the generic classification only for the clearly identified products, set aside the unreasoned classification findings for the remaining goods, and remitted the connected Modvat credit consequences for fresh adjudication.

Ratio Decidendi: Classification of medicaments depends on whether the marking on the product or its packing indicates a trade connection with the manufacturer, and a non-speaking classification order cannot sustain consequential duty reliefs or credit reversals.

---